期刊文献+

人参皂苷C-K乳注射液对新西兰兔的长期毒性试验研究 被引量:6

下载PDF
导出
摘要 目的观察连续静脉滴注给予人参皂苷C-K乳注射液对新西兰兔产生的毒性反应。方法人参皂苷C-K乳注射液72,24,8mg/kg连续静脉滴注给药13周,观察给药期间新西兰兔的一般状况及可能出现的毒性反应,给药13周及停药4周检测新西兰兔血液学指标、血液生化指标及组织病理变化。结果在试验期间各给药组兔进食、活动等一般状况良好;给药13周及停药4周给药组兔各血液学指标与对照组比较未见统计学差异;给药13周血液生化指标检测,高剂量组血清CHO和TG比对照组有明显升高(P<0.01),中剂量组和低剂量组血液生化指标与对照组比较未见统计学差异,停药4周后各给药组血液生化指标与对照组比较未见统计学差异;组织病理学检查高剂量组给药13周见肝细胞肿胀伴灶状坏死,汇管区见炎性细胞浸润及小胆管增生(5/10),肾小管上皮细胞胞浆见透明变性(5/10),其他脏器未见明显病理改变;停药4周后,高剂量组部分肝细胞气球样变,肝细胞灶状坏死(3/6),少量肾小管上皮细胞胞浆见透明变性(3/6),其他脏器未见明显病理改变。结论人参皂苷C-K乳注射液兔静脉给药13周在剂量为72mg/kg(相当于兔等效剂量的20倍)时发现有一定的肝脏、肾脏毒性作用,在剂量24mg/kg(相当于兔等效剂量的6.5倍)及以下剂量未见明显的毒性作用,提示临床试验时应注意肝脏功能及肾功能的变化。
出处 《中国中医药现代远程教育》 2011年第3期188-189,共2页 Chinese Medicine Modern Distance Education of China
  • 相关文献

参考文献4

  • 1Akao T, Kanaoka M, Kobashi K. Appearance of compound K, a major metabolite of ginsenoside Rbl by intestinal bacteria, in rat plasma after oral administration-measurement of compound K by enzyme immunoassay[J]. Biol Pharm Bu11,1998,21(3):245-249.
  • 2邓晶,蒋永新.人参皂苷CK抗肿瘤活性研究进展[J].现代肿瘤医学,2009,17(11):2234-2236. 被引量:18
  • 3中国国家食品药品监督管理局.中药、天然药物长期毒性研究技术指导原则[S].2005.
  • 4国家食品药品监督管理局.中药新药研究指南[S].2004.

二级参考文献25

  • 1Kikuchi Y, Sasa H, Kita T, et al. Inhibition of human ovarian cancer cell proliferation in vitro by ginsenoside Rh2 and adjuvant effects to cisplatin in vivo[J].Anticancer Drugs, 1991,2 ( 1 ) :63 - 67.
  • 2Nakata H, Kikuchi Y, Tode T, et al. Inhibitory effects of ginsenoside Rh2 on tumor growth in nude mice bearing human ovarian cancer cells[J]. Jpn J Cancer Res,1998,89(7) :733 -740.
  • 3Yosioka I, Sugawara T, Imai K, et al. Soll bacterial hydrolysis leading to genuine aglyeone. V. Onginsenosides Rbl, Rb2 and Rc of the ginseng root saponins [ J]. Chem Pharm Bull, 1972,20:2418 - 2421.
  • 4Karikura M, Miyase T, Tanizawa H, et al. Studies on absorption, distribution,excretion and metabolism of ginseng saponinis. VII. Comparison of the decomposition models of ginsenoside - Rb1 and -Rb2 in the digestive tract of rats[JJ. Chem Pharm Bull, 1991, 39(9) : 2357 -2361.
  • 5Hasegawa H, Sung JH, Matsumiya S, et al. Main ginseng saponin metabolites formed by intestinal bacteria [ J]. Planta Med, 1996,62 (5) :453 -457.
  • 6Hasegawa H, Sung JH, Benno Y. Role of human intestinal Prevotella otis in hydrolyzing ginseng saponins [ J]. Planta Med, 1997,63 (5) : 436 -440.
  • 7Akao T, Kida H, Kanaoka M, et al. Intestinal bacterial hydrolysis is required for the appearance of compound K in rat plasma after oral administration of giusenoside Rbl from Panax ginseg[ J]. J Pharm Pharmacol, 1998,50 (10) : 1155 - 1160.
  • 8Chi H, Kim DH, Ji GE, et al. Transformation of ginsenosides Rb2 and Rc from Panax ginseng by food microorganisms[J].Biol Pharm Bull,2005,28( 11 ) :2102 -2105.
  • 9Lee S J, Sung JH, Lee SJ, et al. Antitumor activity of a novel ginseng saponin metabolite in human pulmonary adenoeareinoma cells resistant to cisplatin [J]. Cancer Lett, 1999,144 ( 1 ) : 39 - 43.
  • 10Choi HH, Jone HS, Park JH, et al. A novel ginseng saponin metabolite induces apoptosis and downregulates fibroblast growth factor receptor 3 in myeloma cells [ J ]. Int J Oncol, 2003,23 ( 4 ) : 1087 - 1093.

共引文献17

同被引文献120

引证文献6

二级引证文献84

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部